1. Serum beta‐secretase 1 (BACE1) activity increases in patients with mild cognitive impairment
- Author
-
Valentina Rosta, Patrizia Guasti, Tommaso Romagnoli, Salvatore Pacifico, Giovanni Zuliani, Michele Polastri, Gloria Brombo, Chiara Pistolesi, Remo Guerrini, Alessandro Trentini, Davide Seripa, Dario Pedrini, Carlo Cervellati, and Lisa Marabini
- Subjects
Male ,medicine.medical_specialty ,behavioral disciplines and activities ,Biochemistry ,Gastroenterology ,NO ,Cellular and Molecular Neuroscience ,mild cognitive impairment ,Cerebrospinal fluid ,Atrophy ,Alzheimer Disease ,Internal medicine ,mental disorders ,80 and over ,Aspartic Acid Endopeptidases ,Humans ,Medicine ,Dementia ,Cognitive Dysfunction ,Effects of sleep deprivation on cognitive performance ,Aged ,Aged, 80 and over ,biology ,business.industry ,Neurodegeneration ,Hazard ratio ,Brain ,BACE1 ,medicine.disease ,Confidence interval ,Beta-secretase 1 ,Disease Progression ,biology.protein ,Female ,progression ,Amnesia ,Amyloid Precursor Protein Secretases ,business ,Biomarkers ,Psychomotor Performance ,dementia ,Follow-Up Studies - Abstract
Beta-secretase 1 (BACE1) is considered as the key enzyme in amyloid-β formation. Previous works suggest that high BACE1 activity may be present in brain, cerebrospinal fluid and serum of patients with late-onset Alzheimer's disease (LOAD) as well as mild cognitive impairment (MCI). Therefore, we evaluated whether serum BACE1 activity increases in MCI patients and is associated with the progression from MCI to dementia. BACE1 activity was measured in the serum of 259 MCI patients (162 amnestic-aMCI, 97 non-amnestic-naMCI) and 204 healthy Controls. After a median follow-up of 32 months (range: 10-153), 116 MCI progressed to dementia (87 aMCI and 29 naMCI). Serum BACE1 activity was higher in MCI compared with Controls (p
- Published
- 2021